Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
3.0
Journals
Diagnostics
Special Issues
Diagnosis and Management of Hematologic Malignancies
share announcement

Diagnosis and Management of Hematologic Malignancies

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 810

Special Issue Editor

Dr. Ankur Varma

E-Mail Website
Guest Editor
Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Interests: acute myeloid leukemia; Hodgkin's lymphoma; myelodysplastic syndrome; chronic myeloid leukemia

Special Issue Information

Dear Colleagues,

Hematologic malignancies encompass a diverse group of myeloid and lymphoid cancers. They are broadly classified into myeloid (AML, MDS/MPN, CML) and lymphoid malignancies (ALL, CLL, lymphoma, and myeloma). With the increase in our understanding of the pathogenesis and molecular insights of these malignancies, much of the diagnosis and treatment has shifted to genetic analysis, cellular, and immunotherapy. Bispecific antibodies and CAR T cells have probably been one of the most significant developments for B cell malignancies and multiple myeloma in the last decade. These therapies are well tolerated even in the elderly and frail people and more and more patients are now eligible to get these treatments, resulting in increased survival. This research topic aims to address the specific gaps and challenges, identify the current approaches, and suggest innovative measures for diagnosing and managing hematologic malignancies. In addition to adult hematology, preference will also be given to articles focusing on pediatric populations as there are subtle yet important differences in the management of these two populations. Articles can include, mini-reviews, reviews, systemic reviews, or original research.

Dr. Ankur Varma
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • acute myeloid leukemia
  • chronic myeloid leukemia
  • myelodysplastic syndrome
  • myeloproliferative neoplasm
  • Hodgkin's lymphoma
  • non-Hodgkin's lymphoma
  • acute lymphocytic leukemia
  • chronic lymphocytic leukemia
  • bone marrow failure syndrome
  • juvenile myelomonocytic leukemia

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

18 pages, 1859 KiB  
Article
Modified Endothelial Activation and Stress Index: A New Predictor for Survival Outcomes in Classical Hodgkin Lymphoma Treated with Doxorubicin-Bleomycin-Vinblastine-Dacarbazine-Based Therapy
by Fazıl Çağrı Hunutlu, Hikmet Öztop, Vildan Gürsoy, Tuba Ersal, Ezel Elgün, Şeyma Yavuz, Selin İldemir Ekizoğlu, Azim Ali Ekizoğlu, Vildan Özkocaman and Fahir Özkalemkaş
Diagnostics 2025, 15(2), 185; https://doi.org/10.3390/diagnostics15020185 - 14 Jan 2025
Viewed by 596
Abstract
Background: Although the cure rates of classical Hodgkin Lymphoma (cHL) are as high as 90% using the current treatment protocols, the prognosis is poor for primary refractory patients. Thus, a biomarker that can predict patients with early progression at the time of diagnosis [...] Read more.
Background: Although the cure rates of classical Hodgkin Lymphoma (cHL) are as high as 90% using the current treatment protocols, the prognosis is poor for primary refractory patients. Thus, a biomarker that can predict patients with early progression at the time of diagnosis is an unmet clinical need. Endothelial activation and stress index (EASIX) and its variant modified EASIX (mEASIX) is a scoring system currently used for the prediction of prognosis in hematologic malignancies. This study aimed to investigate the prognostic value of the mEASIX score in newly diagnosed cHL patients. Methods: Data from 206 patients who underwent positron emission tomography (PET)-guided doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) therapy for cHL between January 2007 and November 2023 were retrospectively analyzed. The prognostic value of the mEASIX score was evaluated using the receiver operating characteristic (ROC) analysis, Cox regression analysis, and the Kaplan–Meier method, and then compared with standard risk assessment methods. Results: The median age at diagnosis was 33 years, and the rate of patients in the advanced stage was 67%. ROC analysis determined an optimal mEASIX score cut-off of 17.28, categorizing patients into mEASIXhigh (47%) and mEASIXlow (53%) groups. The 5-year progression-free survival (PFS) (60% vs. 84.3%) and overall survival (OS) (79.6% vs. 95.8%) were significantly lower in the mEASIXhigh group (p < 0.001). Additionally, multivariate analysis showed that the independent variables affecting PFS included the nodular sclerosing subtype (HR: 0.4), bone marrow involvement (HR: 2.6), and elevated mEASIX (HR: 3.1). Independent variables, which had an effect on OS included elevated mEASIX (HR:3.8) and higher IPS-3 scores (HR:1.9). Furthermore, a higher mEASIX score (≥17.28) was identified as an independent variable indicating primary refractory disease (OR: 6.5). Conclusions: mEASIX is a powerful and easy-to-access marker for the detection of primary refractory disease and prognosis in newly diagnosed cHL cases. Full article
(This article belongs to the Special Issue Diagnosis and Management of Hematologic Malignancies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop